Dr. Sean Lyden, vascular surgeon and Chairman of Vascular Surgery at Cleveland Clinic, discusses the breakthrough therapy of percutaneous transarterial bypass (PTAB) for treating occlusive/stenotic superficial femoral artery (SFA) disease. They cover the DETOUR trials, DVT and PE risks, patency of femoral vein following DETOUR intervention, and future directions of the FDA-approved DETOUR device.